Researchers developed a novel radioiodinated PSMA-targeting radiopharmaceutical that can be produced in high yields without generating volatile byproducts. The agent shows exceptional effectiveness for precision diagnosis and treatment of prostate cancer in preclinical studies, targeting prostate-specific membrane antigen (PSMA).
Researchers used a novel imaging agent to visualize inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction. The study found a systemic inflammatory response, suggesting a potential mechanism for disease progression and therapy response.
Peter S. Conti, MD, PhD, received the 2020 Benedict Cassen Prize for his pioneering work in radiopharmaceuticals and clinical PET applications for cancer imaging. The award recognizes his contributions to advancing nuclear medicine and molecular imaging.
A multicenter trial found that PSMA PET/CT identified disease in over half of patients with negative conventional imaging, leading to changes in management in 66% of cases. The most common changes were conversion to surgery or radiation, or addition of nodal-directed therapy.
Stephen L. Bacharach, PhD, is recognized for his contributions to gated cardiac blood pool imaging, informatics, and data processing. His research has had a significant impact on nuclear medicine and cardiology.
A new radiotracer measures synaptic density changes in the brain after stroke, providing an objective and quantitative measure of disease progression. This method may also help detect stroke early and evaluate recovery.
A new study using uEXPLORER technology successfully detected metastatic cancer in patients, providing high-quality images of tumor behavior. Parametric images showed improved visibility of cancer lesions detection and multi-parametric characterization of tumor metastases.
A new molecular imaging approach using PET/MRI has been developed to precisely identify the location of pain generators in chronic pain patients. This approach resulted in a significant modification of management plans for nearly half of the patients, with some receiving invasive procedures.
A new PET radiotracer has been proven safe and effective in imaging malignant brain tumors with high sensitivity. The radiotracer targets αvβ3 integrin, which is overexpressed in glioblastomas, allowing for superior visualization of tumors.
Carolyn J. Anderson, PhD, has been recognized for her pioneering work in radiometal-based radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of cancer and other diseases. Her research focuses on developing imaging agents for upregulated receptors on immune cells involved in inflammation related to lung diseases.
Targeted radionuclide therapy has been shown to improve the effectiveness of immunotherapies in treating prostate cancer by modifying the tumor microenvironment. The treatment can achieve immunomodulation at relatively low radiation doses without affecting the normal immune system.
The uEXPLORER TB-PET/CT scanner offers a new imaging option for inflammatory arthritis by capturing glucose metabolism in normal and diseased joint tissues across the body. This allows for quantifying systemic inflammatory burden, which could have direct implications for disease staging, treatment selection, and monitoring of treatment...
A new radiotracer, 68Ga-DOTA-JR11, has shown excellent imaging performance in detecting liver metastases and providing important information to guide treatment. The study found that 68Ga-DOTA-JR11 performed better than 68Ga-DOTATATE PET/CT in detecting liver lesions, with a higher tumor-to-background ratio.
The COVID-19 pandemic has accelerated the adoption of telemedicine in nuclear cardiology, enabling continued service during outbreaks. Nuclear medicine also offers potential for repurposing pharmaceuticals and developing new treatments targeting different aspects of the virus.
Research identified potentially treatable genetic mutations in prostate cancer patients who did not respond to PSMA-targeted therapy. Targeted next-generation gene sequencing found mutations in six out of seven patients, including alterations in DNA damage-repair genes such as TP53, ATM, and CHEK2.
Researchers used molecular imaging to track DNA damage in neuroendocrine tumors treated with 177Lu-DOTATATE. The technique enabled visualization of γH2AX foci just days after treatment, providing insights into therapeutic outcomes and potential dose adjustments.
Researchers have found that the new radiotracer 18F-PSMA-1007 offers advantages over established agent 68Ga-PSMA-11 in staging prostate cancer. The study showed near-equal performance between the two tracers, with 18F-PSMA-1007 detecting additional lesions in four patients.
Patients receiving 177Lu-DOTATATE radiation therapy may experience travel delays at U.S. ports of entry due to residual radiation activity; carrying a travel card with treatment information can help alleviate this issue.
The global nuclear medicine community has shared approaches to containing the spread of COVID-19, including triage, reduced elective studies, improved hygiene practices, and rotation of medical personnel. These measures aim to minimize patient contact and optimize distance to reduce the risk of transmission.
Researchers used total-body PET imaging to track the distribution of 89Zr-labeled antibodies in preclinical trials, achieving excellent image quality up to 30 days after injection. The study demonstrates the potential of this technique for extended imaging windows and low-dose radioactivity.
Researchers found reduced glucose metabolism in the brain stem and primary auditory cortex of patients with asymmetric hearing loss. Long duration of hearing impairment was associated with higher glucose metabolism on the contralateral side.
Researchers used PET myocardial perfusion imaging to quantify myocardial blood flow and flow reserve, successfully detecting cardiac allograft vasculopathy and predicting prognosis. The study found MFR had higher accuracy in predicting overall prognosis for cardiac transplant patients.
A new radiopharmaceutical, [55Co]Co-DOTATATE, has been developed to aid in the diagnosis of neuroendocrine tumor metastases. It resulted in superior image contrast and enhanced detection compared to commonly used imaging agents.
A new therapy option has been identified for early-stage breast cancer using the radiopharmaceutical 223RaCl2, which delays the growth of disseminated tumor cells. The treatment shows promise in delaying tumor progression and may be an adjuvant therapy option for select patients.
Researchers have identified several potentially useful breast cancer biomarkers that indicate the presence and risk of malignancy. PET/MRI imaging revealed differences in biomarkers between healthy contralateral breast tissue of patients with malignant and benign breast tumors.
A new radiotracer, 68Ga-FAPI-04 PET, can effectively image fibroblast activation after myocardial infarction, identifying a time window during which cardiac fibrosis can be prevented. This technology may aid in the clinical management of patients after a heart attack.
A new non-invasive imaging technique using 89Zr-immuno-PET can measure target engagement of therapeutic antibodies in tumors, enabling personalized treatment. This method provides a significant advance over current invasive methods and has important implications for patient care.
A novel theranostic reagent has been developed to detect and treat metastatic prostate cancer, achieving high imaging accuracy. The reagent targets STEAP1 antigen, identifying lesions in patients with a significant number of positive results.
Researchers discovered a new way to optimize PSMA-targeted prostate cancer treatment by adjusting peptide concentrations, reducing tumor uptake and salivary gland damage. The study suggests that setting an optimal molar activity level can minimize adverse effects while maintaining therapeutic efficacy.
A study has developed a method to determine activity in bone marrow, enabling personalized dosimetry. This approach can predict the effectiveness of treatment and prevent bone marrow toxicity.
Researchers developed a novel noninvasive imaging technique using multispectral optoacoustic tomography (MSOT) and ultrasound to diagnose thyroid disorders. MSOT/ultrasound images revealed significant biomarker changes in Graves' disease and malignant thyroid nodules, showing promise for improved diagnostics.
A new study finds that 68Ga-DOTATATE PET/CT is a more accurate method for selecting patients with neuroendocrine tumors who may benefit from peptide receptor radionuclide therapy. The imaging modality yields significantly higher Krenning scores and detects eligible patients with smaller lesions.
The Journal of Nuclear Medicine has seen a significant increase in its impact factor, with a jump of 25% compared to the previous year. The journal's immediacy index also increased, indicating a faster pace of citation activity.
Researchers found PRRT to be safe and effective for patients with grade 3 neuroendocrine neoplasms, with a median progression-free survival rate of 9.6 months and overall survival rate of 19.9 months. Patients with low Ki-67 index responded more favorably to PRRT.
Researchers have developed ultrasmall nanoclusters with antioxidative properties that can pass through the kidneys' filtration barrier to alleviate clinical symptoms of AKI. Selenium-doped carbon quantum dots also demonstrated effective treatment and prevention of AKI in mice by localizing in the kidneys and eliminating ROS.
Research presented at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting found that tobacco smokers have reduced neuroimmune function compared to nonsmokers. This impairment may contribute to compulsive drug use and cognitive dysfunction in smokers trying to quit.
A novel combination therapy using two targeted treatments has shown to maximize efficacy while reducing side effects in men with progressive prostate cancer. The study found that nearly 70 percent of patients saw a more than 50 percent reduction in PSA levels after the treatment.
A novel radiotracer has been identified that can detect nearly 30 types of cancer using positron emission tomography/computed tomography (PET/CT). This technology shows promise for new applications in noninvasive diagnosis, staging and treatment.
The Society of Nuclear Medicine and Molecular Imaging announced 13 new SNMMI Fellows, recognizing their outstanding contributions to the field. The recipients include past SNMMI presidents and experts in various areas of nuclear medicine and molecular imaging.
Researchers used PET/CT to evaluate coronary microvascular function in OSA patients and found a link between severe sleep apnea and impaired coronary flow reserve. The study suggests that patients with severe OSA should receive PET myocardial perfusion imaging to exclude coronary microcirculatory dysfunction.
Researchers developed a wearable vest to collect data for personalized therapy in patients with metastatic NETs. The device provides organ-specific measurement recordings within the patient's comfort, allowing for more effective treatment and improved progression-free survival.
A new class of radiopharmaceuticals, named radiohybrids (rh), has been developed for cancer imaging and radioligand therapy (theranostics). These rhPSMA-ligands have a unique feature that both fluorine and the metal are always present, but only one of them is present as a radioactive isotope.
Research shows that adding an interim scan during therapy can help guide patient treatment, predicting survival and tumor response. Interim scans using PSMA PET imaging have shown significant predictive value for overall survival in patients undergoing 177Lu-PSMA radioligand therapy.
A study using PET imaging reveals that women with the ApoE 4 allele are more susceptible than men to tau accumulation in the brain. The study also found that sex modulates the effect of ApoE ε4 on brain tau depositing in individuals with mild cognitive impairment.
A study found that PET/CT imaging can identify diseased areas in patients with extra-pulmonary tuberculosis, guiding personalized therapy. The test provides a whole-body survey, helping to estimate disease extent and predict treatment response.
Di Carli is recognized as an outstanding clinician-scientist, teacher, and mentor, known for pioneering work in cardiovascular radionuclide imaging and services. His research has contributed to understanding ischemic cardiac dysfunction and using positron emission tomography (PET) for guiding management of patients with end-stage heart...
A first-in-human Phase 1/Phase II study demonstrates the safety and efficacy of intravenous administration of technetium-99m tilmanocept for monitoring rheumatoid arthritis disease activity. The imaging agent binds to activated macrophages, providing joint-specific information on RA disease involvement.
Jason S. Lewis, PhD, has received the 2019 Paul C. Aebersold Award from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) for his outstanding contributions to basic nuclear medicine science. His research focuses on developing radiopharmaceuticals for targeted diagnosis and treatment of cancer.
Researchers developed a new type of nuclear medicine scan that quickly and precisely diagnoses inflammation in IBD using monoclonal antibodies directed against specific innate immune cell markers. The immuno-PET scan has high potential for theranostic diagnosis and precision treatment of IBD and other inflammatory diseases.
A novel radiopharmaceutical has proven effective in identifying nearly 30 types of malignant tumors with high uptake and image contrast. The tracer targets cancer-associated fibroblasts, which can contribute up to 90% of a tumor's mass.